In Japanese clinical practice guidelines for prostate cancer, combined androgen blockade (CAB) therapy, which involves concurrent use of a gonadotropin-releasing hormone (GnRH) agonist and first-generation antiandrogen, such as bicalutamide, is recommended as the standard first-line therapy for metastatic prostate cancer. Here, GNRH1 is linked to prostate carcinoma.